BioCentury
ARTICLE | Company News

China's SARI acquiring Nerviano

December 29, 2017 11:03 PM UTC

China investment company SARI will acquire a 90% stake in cancer company Nerviano Medical Sciences s.r.l. (Nerviano, Italy) for about €300 million ($356.3 million), which includes an equity investment and a debt restructuring. The deal is expected to close in 1Q18. SARI is an affiliate of the Shanghai Advanced Research Institute.

Shanghai Advanced Research Institute was established by the Chinese Academy of Sciences and the Shanghai Municipal Government in 2012. Its life sciences research division is focused on medical imaging technology, stem cell therapies, nanomedicine and targeted cancer therapies...